<DOC>
	<DOCNO>NCT00001426</DOCNO>
	<brief_summary>A supra-additive cytotoxic effect see CAI paclitaxel give human ovarian cancer cell sequentially tissue culture . We demonstrate CAI give 8 day follow paclitaxel reasonably well tolerate paclitaxel administration cause dose-dependent increase CAI plasma concentration . CAI cytostatic drug continuous exposure need . This study evaluate combination continuously administer CAI three-weekly paclitaxel .</brief_summary>
	<brief_title>A Multi-Institutional Phase II Study Cyclophosphamide , Paclitaxel , Cisplatin With G-CSF Patients With Newly Diagnosed Advanced Stage Ovarian Cancer</brief_title>
	<detailed_description>A supra-additive cytotoxic effect see CAI paclitaxel give human ovarian cancer cell sequentially tissue culture . We demonstrate CAI give 8 day follow paclitaxel reasonably well tolerate paclitaxel administration cause dose-dependent increase CAI plasma concentration . CAI cytostatic drug continuous exposure need . This study evaluate combination continuously administer CAI three-weekly paclitaxel .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<criteria>INCLUSION CRITERIA : All patient must biopsy proven , newly diagnose epithelial ovarian cancer , primary epithelial fallopian tube cancer , peritoneal surface carcinoma . Histopathologic diagnosis must confirm pathology department treat institution prior initiation therapy . Diagnosis confirm Laboratory Pathology , National Cancer Institute . This confirmation necessary prior enter patient onto protocol . Patients must FIGO stage III IV disease undergo attempt surgical debulking prior initiation chemotherapy . Patients must able begin therapy within 6 week stag laparotomy indwell venous access device place . A double lumen catheter prefer . Performance status less equal ECOG 2 . Patients must able give write informed consent express willingness meet expect requirement protocol . All patient must register call Orkand Corporation 3014021732 hour 8:30 AM 5:00 PM EST ; Eligibility criterion query . EXCLUSION CRITERIA : Evidence CNS involvement ( patient normal clinical exam require head CT scan MRI ) . History myocardial infarction unstable dysrhythmia within 1 month study entry . Creatinine clearance le 60 cc/min , ANC le 1000/cm3 , platelet count less 1000,000/cm3 . History active GI bleeding within last 30 day . Prior therapy surgery malignancy . Abnormal PT , PTT , bilirubin . SGOT great equal 3 time upper limit normal . Previous history invasive malignancy . Patients ureteral obstruction must correct prior start therapy . Patients germ cell , mixed Muellerian borderline histology specifically exclude .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 7, 2013</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Initial Therapy</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Cyclophosphamide</keyword>
</DOC>